Bavarian Nordic Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Bavarian Nordic yıllık ortalama 37.7% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler growing yılda ortalama 41.2% oranında artmaktadır. Bavarian Nordic'in özkaynak karlılığı 10.5% ve net marjı 18.4%'dir.

Anahtar bilgiler

37.7%

Kazanç büyüme oranı

32.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	18.7%
Gelir büyüme oranı	41.2%
Özkaynak getirisi	10.5%
Net Marj	18.4%
Sonraki Kazanç Güncellemesi	05 Mar 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Nov 16

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Gelir ve Gider Dağılımı

Bavarian Nordic nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CPSE:BAVA Gelir, gider ve kazançlar (DKK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	6,070	1,119	874	1,663
30 Jun 24	6,083	707	796	1,821
31 Mar 24	6,642	984	805	2,115
31 Dec 23	7,062	1,475	751	2,228
30 Sep 23	5,906	723	757	1,757
30 Jun 23	5,533	1,076	745	1,695
31 Mar 23	4,083	301	630	1,376
31 Dec 22	3,151	-347	589	1,183
30 Sep 22	2,404	-599	509	755
30 Jun 22	1,849	-693	484	470
31 Mar 22	1,683	-606	476	382
31 Dec 21	1,898	-465	485	399
30 Sep 21	1,583	-737	502	409
30 Jun 21	1,693	-629	542	437
31 Mar 21	2,022	-368	561	397
31 Dec 20	1,852	278	564	341
30 Sep 20	1,914	606	488	325
30 Jun 20	1,499	481	398	314
31 Mar 20	901	267	303	350
31 Dec 19	662	-347	227	387
30 Sep 19	554	-402	217	398
30 Jun 19	631	-271	211	379
31 Mar 19	616	-279	215	373
31 Dec 18	501	-362	214	386
30 Sep 18	360	-445	218	422
30 Jun 18	873	-151	209	511
31 Mar 18	1,184	5	206	535
31 Dec 17	1,370	181	208	518
30 Sep 17	1,745	453	205	512
30 Jun 17	1,463	225	214	482
31 Mar 17	1,182	153	211	459
31 Dec 16	1,007	31	213	463
30 Sep 16	909	-54	215	402
30 Jun 16	536	-202	204	349
31 Mar 16	808	-115	205	373
31 Dec 15	1,021	59	217	375
30 Sep 15	1,244	155	229	462
30 Jun 15	1,390	186	244	507
31 Mar 15	1,166	70	242	496
31 Dec 14	1,217	26	226	479
30 Sep 14	1,013	-99	204	425
30 Jun 14	1,107	-61	198	406
31 Mar 14	1,293	-12	198	512
31 Dec 13	1,213	-47	198	497

Kaliteli Kazançlar: BAVA yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: BAVA 'nin mevcut net kar marjları (18.4%) geçen yılın (12.2%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BAVA son 5 yılda karlı hale geldi ve kazançlarını yıllık 37.7% oranında artırdı.

Büyüme Hızlandırma: BAVA 'un son bir yıldaki kazanç büyümesi ( 54.6% ) 5 yıllık ortalamasını (yıllık 37.7% ) aşıyor.

Kazançlar vs. Sektör: BAVA geçen yılki kazanç büyümesi ( 54.6% ) Biotechs sektörünün -20.8% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: BAVA 'nin Özsermaye Getirisi ( 10.5% ) düşük olarak değerlendiriliyor.

Bavarian Nordic Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock